Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06603285

A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin

This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary arterial hypertension.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Pulmonary Arterial Hypertension Hypertension, Pulmonary Lung Diseases Respiratory Tract Diseases

Sex eligibility

All sexes

Study type

Observational

About this study

This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The expected study period will be 2 years. PAH patients, who met NHI criteria, to receive treprostinil subcutaneously/ intravenously, will be invited to join this study for observation. The dosage and administration schedule of study medication will be judged by investigators. If the eligibility criteria have been met and the subject have signed the informed consent, the subjects will be enrolled into this study. There will be 10 visits: Visit 1 (Screening visit, Week -2 ~ -1), Visit 2 (Week 1, initial of use treprostinil), Visit 3 to 9 (Week 13 to 85), Visit 10 (Week 97). The Day 1 in Week 1 should be the start day of treprostinil treatment. Subjects will be returned to the clinics every 3 months (i.e. 12 weeks) after Visit 2. The NT-proBNP level, WHO functional class, 6-minute walk distance, echocardiography, pulse oximetry, modified Borg Dyspnea Scale, SF-36 questionnaire, and dosage regimens of treprostinil (including dose adjustment) will be collected. For time to clinical worsening and death, it will be followed up during study period. All intercurrent events within 24 months will be recorded. Safety information, including vital signs, and physical exams will be checked. Adverse events of special interest (AESIs) will be reviewed every visit by using a predesignated AESI checklist.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with symptomatic idiopathic or heritable PAH classified as WHO functional class III and IV symptoms.
  • PAH patient, who met NHI criteria, will be scheduled to receive subcutaneous/intravenous treprostinil treatment.
  • Ability to adhere to the study visit schedule and understand and comply with all protocol requirements.
  • Will provide completed and signed written informed consents

Exclusion criteria

  • Active treatment with injectable prostanoids different from subcutaneous/intravenous treprostinil

Treatment and study plan

Treprostinil

Drug

sc/iv continuously

Other names: Remodulin

Primary outcomes

  1. Change from baseline in NT-proBNP

    Time frame: Week 97

    Calculate the "N terminal pro B type natriuretic peptide" change from baseline to Week 97

  2. Change from baseline in WHO functional class

    Time frame: Week 97

    Calculate the World Health Organization functional class change from baseline to Week 97.

    The World Health Organization (WHO) functional class describes how severe a patient's pulmonary hypertension (PH) symptoms are.

    There are four different classes - I is the mildest and IV is the most severe form of PH.

Secondary outcomes

  1. Time to clinical worsening and death

    Time frame: 96 weeks

    Record the time to clinical worsening and death

  2. Change from baseline in NT-proBNP

    Time frame: Week 13, 25, 37, 49, 61, 73, and 85

    Calculate the change from baseline in NT-proBNP at Week 13, 25, 37, 49, 61, 73, and 85

  3. Change from baseline in 6-minute walk distance (6MWD)

    Time frame: Week 25, 49, 73, and 97

    Calculate the cange from baseline in 6-minute walk distance (6MWD) at Week 25, 49, 73, and 97

  4. Trend of dose usage from initiation treatment to clinical worsening

    Time frame: 96 weeks

    Record all the daily doses which the patients administered during the whole study period

  5. Adverse events of special interest (AESIs)

    Time frame: 96 weeks

    AESIs include infusion site pain, infusion site reaction, headache, diarrhea, nausea, rash, jaw pain, hot flashes, vasodilation, and edema

  6. Change from baseline in WHO functional class

    Time frame: Week 13, 25, 37, 49, 61, 73, and 85

    Calculate the change from baseline in WHO functional class at Week 13, 25, 37, 49, 61, 73, and 85 The World Health Organization (WHO) functional class describes how severe a patient's pulmonary hypertension (PH) symptoms are.

    There are four different classes - I is the mildest and IV is the most severe form of PH.

  7. Change from baseline in right atrium (RA) area

    Time frame: Week 25, 49, 73, and 97

    RV structure and function will be monitored by echocardiography, including Right atrium (RA) area.

  8. Change from baseline in TAPSE/sPAP ratio.

    Time frame: Week 25, 49, 73, and 97

    RV structure and function will be monitored by echocardiography, including Tricuspid annular plane systolic excursion (TAPSE) / systolic pulmonary artery pressure (sPAP) ratio.

  9. Change from baseline in Pericardial effusion.

    Time frame: Week 25, 49, 73, and 97

    RV structure and function will be monitored by echocardiography, including Pericardial effusion.

  10. Change from baseline in modified Borg Dyspnea Scale

    Time frame: Week 25, 49, 73, and 97

    Calculate the change from baseline in modified Borg Dyspnea Scale at Week 25, 49, 73, and 97.

    The modified Borg Dyspnea scales are patient self-reported measures of one's difficulty in breathing upon exertion. The Scale is a categorical scale with a score from 0 to 10, where 0 represents normal breathing and 10 represents maximum dyspnea.

  11. Change from baseline in SF-36 questionnaire

    Time frame: Week 25, 49, 73, and 97

    Calculate the change from baseline in SF-36 questionnaire at Week 25, 49, 73, and 97.

    The 36-Item Short Form Survey (SF-36) is an outcome measure instrument that is often used, well-researched, self-reported measure of health. It stems from a study called the Medical Outcomes Study for the objective measure of the quality of life.

    It comprises 36 questions that cover eight domains of health. Scores for the different domains are converted and pooled using a scoring key, for a total score indicating a range of low to high QOL.

  12. Intercurrent event

    Time frame: 96 weeks

    Intercurrent events includes consent withdrawn, use of rescue medication, discontinuation from treprostinil treatment, PAH unrelated hospitalization, switch to other PAH drugs (other than treprostinil), add-on PAH drugs, or new-onset co-morbidity.

Study contacts

Contact information is provided by the study sponsor or research team.

Cliff Lin

CONTACT

[email protected]

+886226557568 ext. 1421

Sponsors and collaborators

Lead sponsor

Excelsior

Industry

Registry information

Official study title

A Multi-center, Prospective Study to Observe the Safety, Tolerability, and Efficacy of Remodulin® in Patients With Pulmonary Arterial Hypertension

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Sep 19, 2024
Registry last updated
Aug 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.